Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 See also  





2 References  














NS-2359






Čeština
Српски / srpski
Srpskohrvatski / српскохрватски
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


NS-2359
Clinical data
ATC code
  • none
Identifiers
  • (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-azabicyclo[3.2.1]octane

PubChem CID
UNII
Chemical and physical data
FormulaC15H19Cl2NO
Molar mass300.22 g·mol−1
3D model (JSmol)
  • Clc1ccc(cc1Cl)C(C2COC)CC3NC2CC3

  (verify)

NS-2359 (GSK-372475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under developmentbyGlaxoSmithKline (GSK) as an antidepressant,[1] but was discontinued in 2009 when phase II clinical trials showed the drug was not effective and not well tolerated.[2] The results did not support further effort by the company.[1] NS-2359 was also in clinical trials for the treatmentofADHD,[3] phase II having been completed in 2007.[4]Aphase I clinical trial exploring the effect of NS-2359 on cocaine-dependent individuals was completed in 2002.[5]

See also[edit]

References[edit]

  1. ^ a b "NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression". NeuroSearch. Archived from the original on 2016-03-04. Retrieved 2009-06-20.
  • ^ Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, Ratti E (May 2012). "Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials". Journal of Psychopharmacology. 26 (5): 653–62. doi:10.1177/0269881111424931. PMID 22048884. S2CID 9365152.
  • ^ Wilens TE, Klint T, Adler L, West S, Wesnes K, Graff O, Mikkelsen B (June 2008). "A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD". Behavioral and Brain Functions. 4: 24. doi:10.1186/1744-9081-4-24. PMC 2442604. PMID 18554401.
  • ^ Clinical trial number NCT00467428 for "Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder" at ClinicalTrials.gov
  • ^ Clinical trial number NCT00032916 for "Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers" at ClinicalTrials.gov
  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=NS-2359&oldid=1225974628"

    Categories: 
    Drugs not assigned an ATC code
    Ethers
    Serotoninnorepinephrinedopamine reuptake inhibitors
    Chlorobenzene derivatives
    Tropanes
    Abandoned drugs
    Nervous system drug stubs
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Chemical articles without CAS registry number
    Articles without EBI source
    Chemical pages without ChemSpiderID
    Chemical pages without DrugBank identifier
    Articles without KEGG source
    Articles without InChI source
    Drugs with no legal status
    All stub articles
     



    This page was last edited on 27 May 2024, at 21:05 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki